Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
9.40
+0.38 (4.21%)
At close: Aug 13, 2025, 4:00 PM
9.44
+0.04 (0.43%)
After-hours: Aug 13, 2025, 5:55 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Amneal Pharmaceuticals stock ranges from a low of $11 to a high of $12. The average analyst price target of $11.5 forecasts a 22.34% increase in the stock price over the next year.
Price Target: $11.50 (+22.34%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +17.02% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | +27.66% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +17.02% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +27.66% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | -4.26% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
3.07B
from 2.79B
Increased by 9.92%
Revenue Next Year
3.30B
from 3.07B
Increased by 7.39%
EPS This Year
0.72
from -0.38
EPS Next Year
0.84
from 0.72
Increased by 17.38%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.5B | 3.8B |
| Avg | 3.1B | 3.3B | 3.6B |
| Low | 2.9B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.4% | 12.9% | 15.7% |
| Avg | 9.9% | 7.4% | 8.4% |
| Low | 5.3% | - | -2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.77 | 0.90 | 1.14 |
| Avg | 0.72 | 0.84 | 1.05 |
| Low | 0.68 | 0.76 | 0.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 25.6% | 35.6% |
| Avg | - | 17.4% | 24.1% |
| Low | - | 6.3% | 8.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.